Clinical Trial
doi: 10.1111/j.1749-6632.1990.tb17819.x.
A randomized trial of dietary intervention with essential fatty acids in patients with categorized cysts
Affiliations
- PMID: 2192634
- DOI: 10.1111/j.1749-6632.1990.tb17819.x
Item in Clipboard
Clinical Trial
A randomized trial of dietary intervention with essential fatty acids in patients with categorized cysts
Ann N Y Acad Sci.
1990.
Abstract
Two hundred women with breast cysts proven by aspiration were entered into a randomized double-blind trial of Efamol (evening primrose oil) at a dose of 6 capsules daily or equivalent placebo dose for a year. Cysts were categorized by initial electrolyte composition, and follow-up continued for 1 year posttherapy. Recurrent cyst formation in the first year was slightly (but not significantly) lower in the Efamol group compared with the placebo-treated group. The Efamol treatment was well tolerated as the dropout rate was only 7% and equal in both the active and placebo groups. The initial electrolyte composition did not predict for cyst recurrence.
Similar articles
-
Plasma fatty acid profiles in benign breast disorders.Br J Surg. 1992 May;79(5):407-9. doi: 10.1002/bjs.1800790511. Br J Surg. 1992. PMID: 1596720 Clinical Trial.
-
A double-blind placebo controlled trial of Efamol Marine on skin and joint symptoms of psoriatic arthritis.Br J Rheumatol. 1994 Oct;33(10):954-8. doi: 10.1093/rheumatology/33.10.954. Br J Rheumatol. 1994. PMID: 7921757 Clinical Trial.
-
Evening primrose oil (Efamol) in the treatment of children with atopic eczema.Drugs Exp Clin Res. 1988;14(4):291-7. Drugs Exp Clin Res. 1988. PMID: 3048953 Clinical Trial.
-
A meta-analysis of randomized, placebo-controlled clinical trials of Efamol evening primrose oil in atopic eczema. Where do we go from here in light of more recent discoveries?Curr Pharm Biotechnol. 2006 Dec;7(6):503-24. doi: 10.2174/138920106779116946. Curr Pharm Biotechnol. 2006. PMID: 17168667 Review.
-
[Therapeutic assessment of the evening primrose].Rocz Panstw Zakl Hig. 1993;44(2-3):139-46. Rocz Panstw Zakl Hig. 1993. PMID: 8016534 Review. Polish.
Cited by
-
Omega-6 fats for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Jul 18;7(7):CD011094. doi: 10.1002/14651858.CD011094.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2018 Nov 29;11:CD011094. doi: 10.1002/14651858.CD011094.pub4. PMID: 30019765 Free PMC article. Updated.
-
Effects of total fat intake on body weight.Cochrane Database Syst Rev. 2015 Aug 7;2015(8):CD011834. doi: 10.1002/14651858.CD011834. Cochrane Database Syst Rev. 2015. PMID: 26250104 Free PMC article.
-
Reduction in saturated fat intake for cardiovascular disease.Cochrane Database Syst Rev. 2020 Aug 21;8(8):CD011737. doi: 10.1002/14651858.CD011737.pub3. Cochrane Database Syst Rev. 2020. PMID: 32827219 Free PMC article.
-
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2020 Feb 29;3(3):CD003177. doi: 10.1002/14651858.CD003177.pub5. Cochrane Database Syst Rev. 2020. PMID: 32114706 Free PMC article.
-
Omega 3 fatty acids for prevention and treatment of cardiovascular disease.Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003177. doi: 10.1002/14651858.CD003177.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2018 Jul 18;7:CD003177. doi: 10.1002/14651858.CD003177.pub3. PMID: 15495044 Free PMC article. Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
